**Graphene oxide can induce in vitro and in vivo mutagenesis**

Yuanyuan Liu¹, Yi Luo², Jing Wu³, Yinsong Wang¹, Xiaoying Yang¹, Rui Yang¹, Baiqi Wang¹, Jinrong Yang¹ & Ning Zhang¹,²

¹Research Center of Basic Medical Science & School of Pharmacy, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), Tianjin Medical University, No. 22 Gixiangtai Road, Heping District, Tianjin 300070, People’s Republic of China, ²Tianjin Cancer Institute and Hospital, Tianjin Medical University, Huanhuxi Road, Hexi District, Tianjin 300060, People’s Republic of China, ³Tianjin Third Central Hospital, No. 83 Jintang Road, Hedong District, Tianjin, China, 300170.

Graphene oxide (GO) has attracted enormous interests due to its extraordinary properties. Recent studies have confirmed the cytotoxicity of GO, and we further investigate its mutagenic potential in this study. The results showed that GO interfered with DNA replication and induced mutagenesis at molecular level. GO treatments at concentrations of 10 and 100 μg/mL altered gene expression patterns at cellular level, and 101 differentially expressed genes mediated DNA-damage control, cell apoptosis, cell cycle, and metabolism. Intravenous injection of GO at 4 mg/kg for 5 consecutive days clearly induced formation of micronucleated polychromic erythrocytes in mice, and its mutagenesis potential appeared to be comparable to cyclophosphamide, a classic mutagen. In conclusion, GO can induce mutagenesis both in vitro and in vivo, thus extra consideration is required for its biomedical applications.

Graphene oxide (GO) has attracted enormous interests due to its extraordinary properties. Recent studies have confirmed the cytotoxicity of GO, and we further investigate its mutagenic potential in this study. The results showed that GO interfered with DNA replication and induced mutagenesis at molecular level. GO treatments at concentrations of 10 and 100 μg/mL altered gene expression patterns at cellular level, and 101 differentially expressed genes mediated DNA-damage control, cell apoptosis, cell cycle, and metabolism. Intravenous injection of GO at 4 mg/kg for 5 consecutive days clearly induced formation of micronucleated polychromic erythrocytes in mice, and its mutagenesis potential appeared to be comparable to cyclophosphamide, a classic mutagen. In conclusion, GO can induce mutagenesis both in vitro and in vivo, thus extra consideration is required for its biomedical applications.

Graphene, firstly isolated from graphite in 2004¹, is a flat monolayer of carbon atoms tightly packed into a two-dimensional (2D) honeycomb lattice. Due to the unique physicochemical properties, high surface area, excellent thermal conductivity, electric conductivity, and strong mechanical strength, graphene and graphene oxide (GO) have shown great promise in many applications, such as electronics, energy storage and conversion, mechanics, and biotechnologies²–⁶. Recently, many studies reported that GO has outstanding potential in the field of biomedicine. GO and PEGylated GO exhibit certain advantages in vitro and in vivo drug delivery, such as high drug loading efficiency, controlled drug release, tumor-targeting drug delivery, and reversal effect against cancer drug resistance⁷–ⁱ⁰. In addition, GO has strong optical absorbance in the near-infrared (NIR) region, thus is suitable for the photothermal therapy¹¹–¹³.

Now, it is possible to manufacture high-quality GO in large scale quantities¹⁴,¹⁵, and its industry production is increasing exponentially. Together with its potential applications in the biomedical field, the biosafety of GO is of critical importance. Many investigations have paid attentions to its biocompatibility¹⁶–¹⁹. At a concentration approximate to 50 μg/mL or higher, GO begins to show the toxicity against erythrocytes, fibroblasts, and PC12 cells. It can induce cell apoptosis, hemolysis, and oxidative stress²⁰–²¹. Surface chemical modification, such as PEGylation, is likely to improve the biocompatibility of GO²²–²⁵. However, the chemical bonds linking GO with modified polymer can be broken down in vivo, thus surface-modified GO can also induce in vivo toxicity.

Several investigations have reported that treatments with carbon nanomaterials, such as nanodiamonds and multiwalled carbon nanotubes, can elevate the expression of p53, MOGG-1, and Rad51, which reflect the chromosomal DNA damage²⁶–²⁸. However, it is not clear whether this DNA damage induced by carbon nanomaterials can cause mutagenesis. GO, due to its unique nanosheet structure, can interact with DNA. The interactions include DNA-intercalation and cleavage²⁹. We therefore hypothesize that GO can perhaps induce mutagenesis and interfere with the flow of genetic information. Such mutagenic effects can be accumulated upon long term use and be passed on to next generation by germline mutation, thus is very dangerous. In this study, we firstly investigated the potential mutagenic effect of GO at molecular, cellular, and animal levels.

**Results**

Preparation and characterization of GO, and its anti-proliferative effect against cells. GO with carboxylic acid group content of 8.1% was prepared from purified natural graphite²⁵, and its chemical structure was shown in Fig. 1a. The synthesized GO showed the irregular morphology with micro-scale under the TEM observation.
Then, GO was dispersed in water and small sized by the sonication, according to our previous protocol\(^2\) (Supplementary information). The morphology and size of GO were characterized by atomic force microscope (AFM) and laser light scattering. Small sized GO had sheet structures and their thickness ranged from 0.7 to 1.5 nm, suggesting a single- or double-layered structure (Fig. 1c). Mean diameter of GO sheets was 156.4 nm and the polydispersity index was 0.386 (Fig. 1d). In addition, GO was also characterized by means of fourier transform infrared (FTIR), Ultra-visible (UV-vis), Raman, X-ray diffraction (XRD) and thermal gravimetric analysis (TG), and all results (Supplementary information) were basically consistent with the previous studies\(^2\)–\(^4\). Next, we evaluated the cytotoxicity of GO by Cell Counting Kit-8 (CCK8) assay. After co-incubation for 48 h, GO exhibited dose-dependent cytotoxicity against MDA-MB-231 human breast cancer cells at concentrations ranging from 100 \(\mu\)g/mL to 500 \(\mu\)g/mL (Fig. 1e).

**GO interfered with DNA replication and induced mutagenesis at molecular level.** It has been reported that GO nanosheets can intercalate efficiently into DNA molecules\(^5\). We therefore hypothesize that GO may interact with genomic DNA and interfere with gene replication. To test this hypothesis, we examined the interaction between GO and genomic DNA. The genomic DNA was extracted, treated with GO at different concentrations for 2 h, and subjected to electrophoresis (Fig. 2a). Intensity of genomic DNA gradually decreased as GO concentration increasing and completely disappeared when GO concentration reached to 600 \(\mu\)g/mL, indicating that GO entirely interacted with genomic DNA. This interaction proceeded at a rapid speed, reaching the maximum effect at 2 h upon GO treatment (Fig. 2b). Next, the effect of GO in DNA replication was examined by polymerase chain reaction (PCR) using 50 ng genomic DNA as a template (Fig. 2c). GO inhibited replication of human glyceraldehyde-3-phosphate dehydrogenase (hGAPDH)
gene in a dose-dependent manner, and completely blocked the replication at 1 \( \mu \)g/mL (total 25 ng GO in each reaction), a dose much lower than that was required to interact with genomic DNA.

We next examined the mutagenic effect of GO on gene replication by PCR assays. 5 ng plasmid DNA containing human gene protein kinase C\( _f \) (PKC\( _f \)) was used as a template for PCR in the presence of GO. As shown in Fig. 3a, band intensity of PCR product reduced when GO concentration increased and could not be detected at GO concentration of 100 ng/mL (total 2.5 ng GO in each reaction). Thus, GO blocked replication when the mass ratio of GO to template DNA was higher than 0.5. PCR product was cloned into pMD19T vectors, and transformed into Escherichia coli (E. coli) DH5\( _\alpha \). The clones of the control and GO-treatment groups were then sequenced to examine the fidelity of gene replication. Mean mutation rate of the control group was 0.38%, probably due to the intrinsic properties of Taq DNA polymerase and the reaction condition (Table 1). GO treatment at 10 ng/mL, insufficient concentration to block replication, induced a 37% increase in mutation rate, reaching 0.52% (Table 1). Mutation types included T \( \rightarrow \) C, C \( \rightarrow \) T, G \( \rightarrow \) A, A \( \rightarrow \) G, G \( \rightarrow \) T, A \( \rightarrow \) T, A \( \rightarrow \) C transitions, and G deletion (Fig. 3b). The above results confirmed mutagenic effect of GO on gene replication at molecular level.

GO interfered with gene expression and induced DNA-damage response, cell apoptosis, and cell cycle changes at cellular level. Microarray experiment was used to examine the impact of GO treatment on gene expression at cellular level. Among 30,000 genes tested (the Affymetrix GeneChip Human Genome U133 Plus 2.0 array), GO treatments at 10 \( \mu \)g/mL and 100 \( \mu \)g/mL induced marked changes of 186 and 3693 gene expression patterns, respectively. 101 genes showing 2-fold or greater expression changes in both two GO treatment groups were then grouped by the complete-kink hierarchical clustering method using Genesight 6.4 (Fig. 4). These genes mainly mediated DNA-damage control, cell apoptosis, cell cycle, and metabolism (Table 2).

To preliminarily confirm above gene expression results, we used western blot analysis and flow cytometry assay to assess DNA-damage, cell apoptosis, and cell cycle changes at cellular level. ATM and Rad51, as DNA repair proteins, remain inactive under the normal conditions and become active upon DNA damage caused by irradiation, oxidative stress, etc. Therefore, the transient increases of ATM and Rad51 expressions are often observed at the beginning of DNA damage\(^{22,23} \). The results of western blot analysis (Fig. 5a) showed that GO treatments at 10 and 100 \( \mu \)g/mL induced aberrant increases of ATM and Rad51 expressions in cells during a short term (1 and 2 h), confirming the occurrence of DNA damage. Fig. 5b
shows the results of the apoptosis evaluation of cells treated with GO for 24 h. Cell apoptosis (Fig. 5b, Q1 + Q2) was clearly observed even at a low GO concentration of 10 μg/mL. With the increase of GO concentration, the fraction of late apoptotic cells (Fig. 5b, Q2) significantly increased, further confirming that GO treatment induced cell apoptosis. Fig. 5c shows the cell cycle distributions determined by the flow cytometry. At GO concentration of 100 μg/mL, the proportion of G0/G1 phase cells increased to 79.0 ± 3.9%, significantly higher (p < 0.01) than that of the negative control (60.7 ± 4.2%), which indicated that cells were arrested at the G0/G1 phase. At the same time, the proportion of cells at S-phase decreased from 24.7% to 8.6 ± 0.8%, suggesting that GO significantly inhibited the DNA synthesis. The above results suggested that GO treatment at 100 μg/mL evidently inhibited the transition from G0/G1 to S phase in cell cycle.

GO induced micronucleated polychromatic erythrocytes (MNPCEs) in mice. Next, we tested the hypothesis that GO could induce mutagenesis at animal level by using micronucleus test. Micronucleus test, developed by Schemid in 1975, is a classical assay for mutagenesis. It measures formation of micronucleated polychromatic erythrocytes (MNPCEs) and directly assesses the frequency of structural or numerical chromosome aberrations. Cyclophosphamide, a potent mutagen, induced formation of MNPCE at 50 mg/kg (Fig. 6b). The micronuclei were round or oval in shape and had a diameter about 1/20 to 1/5 that of PCEs, consistent with previous report. Intravenous injection of GO at 1, 2, 4 mg/kg for 5 consecutive days, corresponding respectively to the total doses of 5, 10 and 20 mg/kg, clearly induced the formation of MNPCE in mice (Fig. 6c–e). As shown in Table 3, the frequencies of MNPCEs in GO treated mice exhibited dose-dependent property, and increased from 2.4 ± 0.74 to 7.0 ± 1.31 per 1000 erythrocytes with GO dose increasing from 5 to 20 mg/kg. There were significant differences between GO treatment groups and the negative control group (1.1 ± 0.64 MNPCEs per 1000 erythrocytes), further confirming the mutagenic effect of GO. Moreover, the calculated ratio of PCE/NCE in bone marrow preparations showed no statistically significant differences when compared to the negative control group, indicating that GO at 20 mg/kg didn’t directly kill erythrocytes (Table 3). Together, the results suggested that GO may not be a dangerous cytotoxin, but is a potential inducer of mutagenesis.

**Discussion**

Several reports have shown that treatments with carbon nanomaterials, such as nanodiamonds and multiwalled carbon nanotubes, can elevate the expressions of p53, MOGG-1, and Rad51, reflecting the chromosomal DNA damage. However, it is currently not clear whether this DNA damage induced by carbon nanomaterials can induce mutagenesis. Due to the unique nanosheet structure of GO and its potential biomedical applications, we paid attentions to its mutagenic effects in this study, and the results confirmed that small sized GO induced mutagenesis both in vitro and in vivo.

At the molecular level, GO interacted with genomic DNA and interfered with DNA replication fidelity. We believed the nanosheet structure of GO made it easily interact with genomic DNA. The highly planar GO nanosheet is very similar to the planar aromatic ring structures of many DNA intercalators, such as berberine, ethidium bromide and proflavine. It was thus deduced that GO could also insert between base pairs of double strand DNA and interfere with DNA replication fidelity. The results suggested that GO may not be a dangerous cytotoxin, but is a potential inducer of mutagenesis.

**Table 1** | Mutation effect of GO on PKCζ gene that assessed by the clone experiment

| Group | Experiment No. | Clone number | Total gene length (bp) | Mutation number (bp) | Mut. Rate* (%) | Mean mut. rate (%) |
|-------|----------------|--------------|-----------------------|---------------------|---------------|-------------------|
| Control | 1 | 32 | 19200 | 7 | 0.36 | 0.38 |
| | 2 | 32 | 19200 | 7 | 0.36 | 0.38 |
| | 3 | 32 | 19200 | 8 | 0.42 | 0.42 |
| GO | 1 | 32 | 19200 | 10 | 0.52 | 0.52 |
| | 2 | 32 | 19200 | 10 | 0.52 | 0.52 |
| | 3 | 33 | 19800 | 10 | 0.51 | 0.51 |

*Mut. rate (mutation rate) was calculated by dividing the mutation number observed by the total gene length.

*Compared to the control, GO-treatment group at 10 ng/mL showed statistically significant difference in mutation rate (p < 0.05).
Table 2 | Genes with differential expressions grouped into potentially relevant functional classes of biologic activity

| Signal pathway               | Deferentially expressed genes with ≥2-fold or greater change |
|-----------------------------|-------------------------------------------------------------|
| DNA damage                  | DDIT4, MYH9, TP53INP1, TP53INP2, HECTD1, SMG1, VCP1P1, MDM4, HPK2, ATM, UBE2N, RAD51, RAD51AP1, RAD51C, PBK, MSH2, MRP63, KCTD6, PSMG1, DUSP12, TP53TG1 |
| Cell cycle                  | USP53, MAP4, GPNMB, PLK1S1, TGFβ1, ATRX, HDAC9, SMK2, FOXK1, MYCBP2, CDKN1A, BCCIP, CCNE2, ID1, ID3, CDK1, CDK2, CDK4, CDK5, CDKN2C, CDKN3, CDC25A, MOSC1, SKP2, PCNA, PKMYT1, PLK4, ANAPC10, ANAPC11, ANAPC13, ANAPC16, GADD45GIPI, ARF3 |
| Cell apoptosis              | CASP4, TMBIM1, ITPR1P2, XIAP, GSK3B, RASA2, RASA4, CREB5, PARP8, MCL1, ULK1, PTEN, MRAS, JAK1, ANTXR1, BCL2L12, HSP90AA1, BID, PARP2, ATG12 |
| Translational control       | PPP1R13L, PPP1R9A, PPP1RAA, EEF2K, EEF1B2, PABPC1I, EEF1A1, EIF2C2, EIF5A2, EIF5B, EIF2AK2, EIF2AK4, EIF1AX, EIF1E1, EIF2B2, EIF4E, EIF4E2, EIF3K, EIF2S1 |
| Cellular metabolism         | GRB10, EHB1P1, MEF2A, MEF2D, PKM2, UCP2, VDAC3, SHCBP1 |

*aRegular and boldface italic font respectively indicate significantly higher and lower expressed genes in both GO treatment groups (10 μg/mL and 100 μg/mL), compared to the control group.

Figure 5 | The induction effects of GO on DNA-damage, cell apoptosis and cell cycle arrest. (a) Western blot analysis of ATM and Rad51 protein expressions in MDA-MB-231 cells treated with GO for 1 and 2 h. (lanes 1–3: the control and GO treatments at 10 and 100 μg/mL). Full-length blots are presented in Supplementary Figure 4. (b) GO treatment induced cell apoptosis. Cells stained with PE annexinV/7-AAD and analyzed by flow cytometry. Q1: dead cells; Q2: late apoptotic cells; Q3: early apoptotic cells; Q4: live cells. (c) GO treatment changed cell cycle distribution based on flow cytometry analysis. All experiments were repeated at least three times. * indicates P < 0.05 for comparison with the control at GO concentration of 0 μg/mL.
with the flow of genetic information like those DNA intercalators. The previous investigations have confirmed that GO nanosheets can intercalate efficiently into DNA molecules. We therefore believed the interaction between GO and DNA was one of the main reasons for the mutagenic effect of GO. In addition, GO and other carbon nanomaterials can induce the cellular generation of reactive oxygen species (ROS), which can also result the potential of DNA damage. Perhaps, there were other indirect mechanisms, because GO could also react with other cell components such as proteins and polysaccharides due to its high surface activity.

At the cellular level, GO altered the expression of a large repertoire of genes at the concentration of 10 \( \mu \text{g/mL} \). Among these genes, ataxia telangiectasia mutated (ATM) protein kinase and recombination protein A (Rad51) are critical components of a DNA-damage response network configured to maintain genomic integrity. ATM- and/or Rad51 differentially expressed cells are characterized by genomic instability including chromosome breaks, chromosome gaps, translocations, and aneuploidy. Caspase 4—apoptosis-related cysteine peptidase (CASP4) plays a central role in the execution-phase of cell apoptosis. Up-regulation of CASP4 expression often induces cell apoptosis. CDK2 and CDK4, members of cyclin-dependent kinases (serine/threonine kinases), play important roles in regulating the cell cycle transition from G1 to S phase, and their down-expressions often increase GO/G1 cell cycle arrest. The next cell experiments confirmed GO treatment could induce DNA-damage and cell apoptosis even at a low dose of 10 \( \mu \text{g/mL} \). However, the significant cell cycle changes were only observed at GO dose of 100 \( \mu \text{g/mL} \), which was potentially due to the adequate DNA-repair effect of ATM and RAD51 proteins.

A number of studies have investigated the biocompatibility and biosafety of GO, showing that GO induced cytotoxicity, oxidative stress, and apoptosis at cellular level, and also caused the lung granuloma formation in mice after a single tail vein injection at a high dose (20 mg/kg) due to its accumulation in the lung. However, our results firstly confirmed that GO induced the formation of MNPCE at the animal level and its potency at the dose of 20 mg/kg was equivalent to that of cyclophosphamide (50 mg/kg), which is a classic mutagen. The mutagenic potential of GO is perhaps a more dangerous threat than the adverse effects listed above, because it is also possible to induce germline mutation that threatens the health of next generation. In a conclusion, the dosage of GO needs to be specially considered during its applications, such as the uses as drug carriers and the photothermal therapeutic agents. According to the previous reports, surface chemical modification is likely to improve the biocompatibility of GO, but the breaking of chemical

---

**Table 3** | Polychromatic erythrocytes with micronuclei (MNPCE) observed in bone marrow cells of female (F) and male (M) mice treated with GO and respective controls

| Groups | Dose (mg/kg) | F1 | F2 | F3 | F4 | M1 | M2 | M3 | M4 | MNPCE (Mean ± SD) | PCE/NCE* (Mean ± SD) |
|--------|-------------|----|----|----|----|----|----|----|----|----------------|------------------|
| Negative | 0          | 0  | 1  | 2  | 1  | 2  | 1  | 0  | 1  | 1.1 ± 0.64       | 1.88 ± 0.25       |
| GO1    | 5          | 2  | 3  | 1  | 3  | 2  | 3  | 2  | 2  | 2.4 ± 0.74*      | 1.78 ± 0.27       |
| GO2    | 10         | 3  | 4  | 5  | 3  | 3  | 2  | 3  | 5  | 3.5 ± 1.07**     | 1.67 ± 0.24       |
| GO4    | 20         | 6  | 8  | 5  | 9  | 7  | 6  | 7  | 8  | 7.0 ± 1.31***    | 1.69 ± 0.34       |
| Positive | 50         | 12 | 10 | 13 | 9  | 10 | 8  | 9  | 11 | 10.3 ± 1.67****  | 1.72 ± 0.18       |

*Two thousand cells were analyzed per animal, for a total of 16,000 cells per group.

**PCE/NCE**: the ratio of polychromatic erythrocytes to normochromatic erythrocytes, and determined on total of 1000 erythrocytes counted.

Significantly different from negative control (\( *P < 0.05 \), \( **P < 0.01 \), and \( ***P < 0.001 \)).
cRNAs were hybridized to gene expression profiles (GeneChip Human Genome (Catalog no. 74104) in accordance with the manufacturers' instructions. Integrity of total cellular RNA of each sample was isolated using QIAGEN RNeasy Mini Kit respectively. Each sample group contained 5 replicates. After incubation for 48 h, the three groups and incubated with GO at concentrations of 0, 10, and 100 μg/mL to examine the impact of GO treatment on gene expression. MDA-MB-231 cells were divided into white-blue screening and sequenced using bi-directional sequencing method (Beijing extraction from 1% agarose gel using a Genomic DNA Extraction kit (TaKaRa, 12.5 μL of a loading buffer solution (0.05% bromophenol blue, 1% SDS, and 50% glycerol, pH 8.0) and then subjected to electrophoresis on a 0.8% agarose gel containing 50 μg of ethidium bromide (EB) in 40 mL of TBE buffer (89 mM Tris, 89 mM boric acid, and 2 mM EDTA, pH 8.3) at 100 V for approximately 1 h. Agarose gel electrophoresis was carried out with JUNYI-SPAT electrophoresis apparatus (Beijing Junyi-Dongfang, China). The agarose gels were imaged using a GelDoc-ITM Imaging System (UVPh Inc., America).

The effects of GO nanosheets in DNA replication. Polymerase chain reaction (PCR) was used to examine the effects of GO in DNA replication using human gliceraldehyde-3 phosphate dehydrogenase (GAPDH) gene as a template. Briefly, genomic DNA above extracted (0.05 g of ethidium bromide (EB) in 40 mL of TBE buffer) was used as the PCR template. The primers were as follows: forward: 5'-GCCACTAGGCGCTCACTGTTCT-3' and reverse: 5'-TGAGGTGCGTGCACCTAGTGG-3'. PCR reaction was carried out in one cycle at 94°C for 3 min and subsequently 30 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min. PCR products were detected on a 1% agarose gel, which was then imaged using the GelDoc-ITM Imaging System (UVPh Inc., America).

Mutation assay. The effect of GO on the fidelity of gene replication was examined by PCR of PKCε followed by sequencing. Plasmids expressing PKCε were amplified by PCR at various GO treatments. PCR reactions were performed in a total volume of 25 μL containing 1.2 μL of plasmid, 1 μL of 20 μM primer (0.05 μg) was incubated with different doses of GO (0, 200, 400, 500, and 600 μg/mL) at 37°C for 2 h, and then amplified in a 25 μL reaction solution containing High Fidelity PCR buffer (10×) with 15 mM MgCl2, 200 μM of each dNTP, 1.25 units of High Fidelity PCR Enzyme Mix, and 0.4 μM of each primer (forward: 5'-GCCACTAGGCGCTCACTGTTCT-3', reverse: 5'-TGAGGTGCGTGCACCTAGTGG-3'). PCR reaction was carried out in one cycle at 94°C for 3 min and subsequently 30 cycles of 94°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min using a Thermocycler Mastercycler Gradient (Eppendorf, Germany). 3 μL of each PCR product was electrophoresed on a 1% agarose gel, which was then imaged using the GelDoc-ITM Imaging System (UVPh Inc., America).

U333 Plus 2.0 Arrays) according to the standard Affymetrix protocol. Integrative comparative and statistical analysis was performed to determine the differentially expressed genes between GO-treatment groups (10 and 100 μg/mL) and control group. RNA expression data CEL files were generated using Affymetrix GeneChip Command Console (AGCC) Software and normalized using Partek Genesignt 6.4 version software. Normalized data were imported into dChip (http://biosun1. nursing complied/dchip/) for differential expression analysis. Two-group comparative analysis was performed using selection variables of at least 2-fold change and t-test at P < 0.05. Samples were permuted 100 times through dChip to assess the false discovery rate. Genes with differential expressions in both two GO treatment groups were then selected and clustered by the hierarchical method.

Western blot analysis. MDA-MB-231 cells were incubated with GO at concentrations of 0, 10, and 100 μg/mL for 24 h. The cells were then washed twice with cold PBS and reseeded in 1× Binding Buffer. Double staining with PE-Annexin V and 7-AAD was carried out using the PE Annexin V Apoptosis Detection Kit (BD Pharmingen™, Franklin Lakes, NJ), according to the manufacturer’s recommendations, and the plates were analyzed within an hour after staining by flow cytometry (Beckman Coulter, USA). Cells were discriminated into viable cells, dead cells, early apoptotic cells, and apoptotic cells by using CellQuest software (BD Biosciences); then the percentages of early apoptotic cells from each experiment were compared.

Cell cycle analysis. Flow cytometry assay was used to assess the changes in cell cycle after GO treatment. MDA-MB-231 cells were spread onto 60 mm tissue culture dishes and incubated to reach 50% confluence. After treatment with different doses of GO for 48 h, cells were digested and washed with PBS (pH 7.4), and then fixed in 70% cold ethanol for 1 h at 4°C. After centrifugation, the cells were washed twice with ice-cold PBS and treated with RNase (0.1 mg/mL), and then stained by propidium iodide (40 μg/mL). Flow cytometric analysis was performed using an EPICS XL flow cytometer (Beckman Coulter, USA), and the cell cycle was analyzed with Cell Quest software.

Micronucleus assay. Next, micronucleus test was used to examined the mutagenic potential of GO. Experiments were carried out using Kunming mice with the weight of 25–30 g that purchased from Wei Tong Li Hua experimental animal (Beijing, China). All experimental procedure was approved by the local animal care committee and was carried out in accordance with the guidelines of the Ethical Committee for Animal Experiments of Tianjin Medical University. The mice were divided into 5 experimental groups (4 females and 4 males) and kept in a climate-controlled environment (25 ± 4°C, 55 ± 5% humidity). Three group mice were administered intravenously with GO solution at 1, 2 and 4 mg/kg once a day for five consecutive days, corresponding respectively to the total doses of 5, 10 and 20 mg/kg. The other two group mice were respectively received physiological saline solution (0.9% NaCl) as negative and positive controls. After humanitian executions, femur bones of mice were excised and the bone marrow flushed into test tubes, and then the micronucleus assay was carried out following standard protocols, as recommended by Schmid27 and Krishna28. For analysis of the micronucleated cells, 2000 polychromatic erythrocytes per animal were scored to determine the mutagenic property of GO. To detect possible cytotoxic effects, the polychromatic erythrocyte/normochromatic erythrocyte ratio in 200 erythrocytes per mouse was calculated.

Statistical analysis. Each experiment was repeated three times in duplicate. The results were presented as mean ± SD. Statistical differences were evaluated using the t-test and considered significant at P < 0.05.

1. Novoselov, K. S. et al. Electric field effect in atomically thin carbon films. Science 306, 666–669 (2004).
2. Geim, A. K. & Novoselov, K. S. The rise of graphene. Nat. Mater. 6, 183–197 (2007).
3. Geim, A. K. Graphene: status and prospects. Nat. Mater. 6, 385–388 (2007).
4. Liu, Z., Robinson, J. T., Sun, X. & Dai, H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J. Am. Chem. Soc. 130, 10876–10877 (2008).
9.  Yang, K. et al. Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. *Nano Lett.* **10**, 3318–3323 (2010).
10. Wu, J. et al. Graphene oxide used as a carrier for adriamycin can reverse drug resistance in breast cancer cells. *Nanotechnology* **23**, 355101 (2012).
11. Yang, K. et al. Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. *Nano Lett.* **10**, 3318–3323 (2010).
12. Robinson, J. T. et al. Ultrasmall reduced graphene oxide with high near-infrared absorbance for photothermal therapy. *J. Am. Chem. Soc.* **133**, 6825–6831 (2011).
13. Yang, K. et al. Multimodal imaging guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles. *Adv. Mater.* **24**, 1868–1872 (2012).
14. Tung, V. C., Allen, M. J., Yang, Y. & Kaner, R. B. High-throughput solution processing of large-scale graphene. *Nat. Nanotechnol.* **4**, 25–29 (2009).
15. Lu, W. B. et al. High-yield, large-scale production of few-layer graphene flakes within seconds: using chlorosulfonic acid and H2O2 as exfoliating agents. *J. Mater. Chem.* **22**, 8775–8777 (2012).
16. Lv, M. et al. Effect of graphene oxide on undifferentiated and retinoic acid-differentiated SH-SY5Y cells line. *Nanoscale* **4**, 3861–3866 (2012).
17. Wang, K. et al. Biocompatibility of graphene oxide. *Nanoscale Res. Lett.* **6**, 8 (2011).
18. Chang, Y. L. et al. In vitro toxicity evaluation of graphene oxide on A549 cells. *Toxicol. Lett.* **200**, 201–210 (2011).
19. Zhang, X. et al. Distribution and biocompatibility studies of graphene oxide in mice after intravenous administration. *Carbon* **49**, 986–995 (2011).
20. Liu, Z., Robinson, J. T., Sun, X. M. & Dai, H. J. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. *J. Am. Chem. Soc.* **130**, 10876–10877 (2008).
21. Yang, K. et al. In vivo pharmacokinetics, long-term biodistribution and toxicology of PEGylated graphene in mice. *ACS Nano* **5**, 516–522 (2011).
22. Xing, Y. et al. DNA damage in embryonic stem cells caused by nanodiamonds. *ACS Nano* **5**, 2376–2384 (2011).
23. Zhu, L., Chang, D. W., Dai, L. & Hong, Y. DNA damage induced by multilayered carbon nanotubes in mouse embryonic stem cells. *Nano Lett.* **7**, 3592–3597 (2007).
24. Ren, H. et al. DNA cleavage system of nanosized graphene oxide sheets and copper ions. *ACS Nano* **4**, 7169–7174 (2010).
25. Becerril, H. A. et al. Evaluation of solution-processed reduced graphene oxide films as transparent conductors. *ACS Nano* **2**, 463–470 (2008).
26. Yang, X. Y. et al. High-efficiency loading and controlled release of doxorubicin hydrochloride on graphene oxide. *J. Phys. Chem. C* **112**, 17554–17558 (2008).
27. Shan, C. et al. Water-soluble graphene covalently functionalized by biocompatible poly-L-lysine. *Langmuir* **25**, 12030–12033 (2009).
28. Marcano, D. C. et al. Improved synthesis of graphene oxide. *ACS Nano* **4**, 4806–4814 (2010).
29. Shang, J. et al. The Origin of fluorescence from graphene oxide. *Sci. Rep.* **2**, 792 (2012).
30. Herreo, J. A., Valencia, A. & Dopazo, J. A hierarchical unsupervised growing neural network for clustering gene expression patterns. *Bioinformatics* **17**, 126–136 (2001).
31. Schmid, W. The Micronucleus Test. *Mutat. Res.* **31**, 9–15 (1975).
32. Gollapudi, B. R. & McFadden, L. G. Sample size for the estimation of polychromatic to normochromatic erythrocyte ratio in the bone marrow micronucleus test. *Mutat. Res.* **347**, 97–99 (1995).
33. Sun, X. et al. Nano-graphene oxide for cellular imaging and drug delivery. *Nano Res.* **1**, 203–212 (2008).
34. Lerman, L. S. Structural considerations in the interaction of DNA and acridines. *J. Mol. Biol.* **3**, 18–30 (1961).
35. Lerman, L. S. Acidine mutagens and DNA structure. *J. Cell. Physiol.* **64**, S1–S18 (1964).
36. Graves, D. E. & Velea, L. M. Intercalative binding of small molecules to nucleic acid. *Curr. Org. Chem.* **4**, 915–929 (2000).
37. Shiloh, Y. ATM and related protein kinases: safeguarding genome integrity. *Nat. Rev. Cancer* **3**, 155–168 (2003).
38. Lavín, M. F. et al. ATM signaling and genomic stability in response to DNA damage. *Mutat. Res.* **569**, 123–150 (2005).
39. Tarsounas, M., Davies, A. A. & West, S. C. RAD51 localization and activation following DNA damage. *Phil. Trans. R. Soc. Lond. B.* **359**, 87–93 (2004).
40. Joseph, E. K. & Levine, J. D. Caspase signaling in neuropathic and inflammatory pain in the rat. *Eur. J. Neurosci.* **20**, 2896–2902 (2004).
41. Berthet, C. & Kaldas, P. Cdk2 and Cdk4 cooperatively control the expression of Cdk2. *Cell Division* **1**, 10 (2006).
42. Krishna, G. & Hayashi, M. In vivo rodent micronucleus assay: protocol, conduct and data interpretation. *Mutat. Res.* **455**, 155–166 (2000).

**Acknowledgments**

We thank Dr. Yongsheng Chen (Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin, China) for kindly providing GO. This project was supported by grant from the 973 program (2011CB933100), National Science Fund for Distinguished Young Scholars (81125019), National Natural Science Foundation of China (81371471), and the special program of China Postdoctoral Science Foundation (20104308).

**Author contributions**

N.Z. and Y.W. proposed and supervised the project. Y.L. and Y.W. prepared and characterized small sized GO. Y.L. performed cell proliferation experiment, western blotting and the interaction between DNA and GO nanosheets. Y.L. and J.W. performed mutation assay, cell cycle analysis, the effects of GO nanosheets on microarray experiment, and micronucleus assay under supervision of N.Z. and Y.W. R.Y. and B.W. helped with the preparation and characterization of small sized GO, and R.Y. also helped cell cycle analysis and micronucleus assay. X.Y. and J.Y. performed Raman, thermogravimetric and X-ray diffraction analyses. N.Z. and Y.W. analyzed all data and wrote the manuscript. All the authors participated in discussions of the research.

**Additional information**

Supplementary information accompanies this paper at http://www.nature.com/scientificreports

**Competing financial interests:** The authors declare no competing financial interests.

How to cite this article: Liu, Y.Y. et al. Graphene oxide can induce in vitro and in vivo mutagenesis. *Sci. Rep.* **3**, 3469; DOI:10.1038/srep03469 (2013).